Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Minocycline added to subc… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: Randomized RECYCLINE study

Artikel i vetenskaplig tidskrift
Författare P. S. Sørensen
F. Sellebjerg
Jan Lycke
M. Färkkilä
A. Créange
C. G. Lund
M. Schluep
J. L. Frederiksen
E. Stenager
C. Pfleger
E. Garde
E. Kinnunen
K. Marhardt
Publicerad i European Journal of Neurology
Volym 23
Sidor 861-870
ISSN 13515101
Publiceringsår 2016
Publicerad vid
Sidor 861-870
Språk en
Ämnesord Combination therapy, Interferon β, Minocycline, Multiple sclerosis, Randomized controlled trial
Ämneskategorier Neurovetenskaper

Sammanfattning

© 2016 European Academy of Neurology.Background and purpose: Combining different therapies may improve disease control in patients with relapsing-remitting multiple sclerosis (RRMS). This study assessed the efficacy and safety of minocycline added to subcutaneous (sc) interferon (IFN) β-1a therapy. Methods: This was a double-blind, randomized, placebo-controlled multicentre study. Within 3 months (±1 month) of starting sc IFN β-1a 44 μg three times weekly, patients with RRMS were randomized to minocycline 100 mg twice daily or placebo, added to sc IFN β-1a, for 96 weeks. The primary efficacy endpoint was the time to first qualifying relapse. Secondary efficacy endpoints were the annualized relapse rate for qualifying relapses, the number of new/enlarging T2-weighted lesions and change in brain volume [magnetic resonance imaging (MRI) was performed only in a few selected centres]. In addition, a number of tertiary efficacy endpoints were assessed. Results: One hundred and forty-nine patients received minocycline and 155 received placebo; MRI data were available for 23 and 27 patients, respectively. The time to first qualifying relapse did not differ significantly for minocycline versus placebo (hazard ratio 0.85; 95% confidence interval 0.53, 1.35; log-rank = 0.50; P = 0.48). There were no statistically significant differences between the two groups on other efficacy endpoints, although some numerical trends in favour of minocycline were observed. No unexpected adverse events were reported, but more patients discontinued because of adverse events with minocycline versus placebo. Conclusion: Minocycline showed no statistically significant beneficial effect when added to sc IFN β-1a therapy.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?